Sound Bioventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function.
BiotechDeep TechHealthtechLongevityAarhus, DK
Simon Mølgaard(Co-founder & CEO)inAnders Dalby(Co-founder)inMathias Ollendorff(Co-founder)inSimon Glerup(Co-founder)in
Co-investorsIndustrifondenP53 InvestInnovestorSunstone Capital
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmainJohn Glasspool(Chief Executive Officer)in
Co-investorsYsios CapitalBioGeneration VenturesEICEQT Life SciencesInkefUNIIQ+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.